UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12

Seminars in oncology, 2015-08, Vol.42 (4), p.539-548

2015

Volltextzugriff (PDF)

Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy : The Underlying Mechanisms and Clinical Management

Scientifica (Cairo), 2013-01, Vol.2013 (2013), p.1-19

2013

Volltextzugriff (PDF)

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

The New England journal of medicine, 2018-08, Vol.379 (8), p.722-730

2018

Volltextzugriff (PDF)

Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab

PloS one, 2014-02, Vol.9 (2), p.e87705-e87705

2014

Volltextzugriff (PDF)

Clinical updates in neoadjuvant immunotherapy for melanoma before surgery

Expert review of clinical immunology, 2024-08, Vol.20 (8), p.927-943

2024

Volltextzugriff (PDF)

IFN-α in the treatment of melanoma

The Journal of immunology (1950), 2012-10, Vol.189 (8), p.3789-3793

2012

Volltextzugriff (PDF)

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma

Journal for immunotherapy of cancer, 2015-09, Vol.3 (1), p.39-39, Article 39

2015

Volltextzugriff (PDF)

Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial

JAMA : the journal of the American Medical Association, 2014-11, Vol.312 (17), p.1744

2014

Volltextzugriff (PDF)

Sargramostim and immune checkpoint inhibitors: combinatorial therapeutic studies in metastatic melanoma

Immunotherapy, 2021-08, Vol.13 (12), p.1011-1029

2021

Volltextzugriff (PDF)

A Tumor and Immune-Related Micro-RNA Signature Predicts Relapse-Free Survival of Melanoma Patients Treated with Ipilimumab

International journal of molecular sciences, 2023-05, Vol.24 (9), p.8167

2023

Volltextzugriff (PDF)

Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma

Journal of translational medicine, 2018-07, Vol.16 (1), p.184-184, Article 184

2018

Volltextzugriff (PDF)

Tremelimumab: a review of development to date in solid tumors

Immunotherapy, 2013-03, Vol.5 (3), p.215-229

Tarhini, Ahmad A

2013

Volltextzugriff (PDF)

Annual Hospital Volume of High Dose Interleukin-2 and Inpatient Mortality in Melanoma and Renal Cell Carcinoma Patients

PloS one, 2016-01, Vol.11 (1), p.e0147153

2016

Volltextzugriff (PDF)

CTLA-4 blockade and interferon-α induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma

PloS one, 2021-01, Vol.16 (1), p.e0245287-e0245287

2021

Volltextzugriff (PDF)

Cost-Effective Patient Selection for Adjuvant Therapy in Stage IIIA Melanoma

Journal of the American College of Surgeons, 2020-11, Vol.231 (5), p.554-556

2020

Volltextzugriff (PDF)

Immunotherapy of Melanoma

Current molecular pharmacology, 2016-08, Vol.9 (3), p.196-207

Tarhini, Ahmad A

2016

Volltextzugriff (PDF)

CTLA-4 blockade and interferon-[alpha] induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma

PloS one, 2021-01, Vol.16 (1), p.e0245287

2021

Volltextzugriff (PDF)

One-Anastomosis Gastric Bypass Revision for Gastroesophageal Reflux Disease: Long Versus Short Biliopancreatic Limb Roux-en-Y Gastric Bypass

Obesity surgery, 2022-04, Vol.32 (4), p.970-978

2022

Volltextzugriff (PDF)

Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males

Journal of translational medicine, 2022-06, Vol.20 (1), p.253-11, Article 253

2022

Volltextzugriff (PDF)

A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma

Journal of translational medicine, 2014-01, Vol.12 (1), p.19-19

2014

Volltextzugriff (PDF)

Jagged2 targeting in lung cancer activates anti-tumor immunity via Notch-induced functional reprogramming of tumor-associated macrophages

Immunity (Cambridge, Mass.), 2024-05, Vol.57 (5), p.1124-1140.e9

2024

Volltextzugriff (PDF)

The accuracy of predicting survival in individual patients with cancer

Journal of neurosurgery, 2014-01, Vol.120 (1), p.24-30

2014

Volltextzugriff (PDF)

Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab

Journal of translational medicine, 2017-02, Vol.15 (1), p.39-39, Article 39

2017

Volltextzugriff (PDF)

PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposing

BMC bioinformatics, 2023-06, Vol.24 (1), p.266-14, Article 266

2023

Volltextzugriff (PDF)

1 – 25 von 271

Suche als RSS-Feed

Aktive Filter

ThemaOncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(250)
Mit Volltextzugriff
(225)

Publikationsform

Artikel
(263)
Buchkapitel
(4)
Berichte
(2)
Texte
(2)

Sprache

Englisch
(271)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12

Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy : The Underlying Mechanisms and Clinical Management

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab

Clinical updates in neoadjuvant immunotherapy for melanoma before surgery

IFN-α in the treatment of melanoma

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma

Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

Sargramostim and immune checkpoint inhibitors: combinatorial therapeutic studies in metastatic melanoma

A Tumor and Immune-Related Micro-RNA Signature Predicts Relapse-Free Survival of Melanoma Patients Treated with Ipilimumab

Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma

Tremelimumab: a review of development to date in solid tumors

Annual Hospital Volume of High Dose Interleukin-2 and Inpatient Mortality in Melanoma and Renal Cell Carcinoma Patients

CTLA-4 blockade and interferon-α induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma

Cost-Effective Patient Selection for Adjuvant Therapy in Stage IIIA Melanoma

Immunotherapy of Melanoma

CTLA-4 blockade and interferon-[alpha] induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma

One-Anastomosis Gastric Bypass Revision for Gastroesophageal Reflux Disease: Long Versus Short Biliopancreatic Limb Roux-en-Y Gastric Bypass

Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males

A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma

Jagged2 targeting in lung cancer activates anti-tumor immunity via Notch-induced functional reprogramming of tumor-associated macrophages

The accuracy of predicting survival in individual patients with cancer

Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab

PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposing

Aktive Filter

Suchergebnisse filtern